Citations

Clear

1444 citation(s) found for "Petersen, Ronald".

Effects of Apolipoprotein E-ε4 and -ε2 in Amnestic Mild Cognitive Impairment and Dementia in Shanghai: SCOBHI-P
Borenstein, Amy R., Mortimer, James A., Ding, Ding , Schellenberg, Gerard D. , DeCarli, Charles, Copenhaver, Cathleen, Guo, Qihao , Chu, Shugang, Salmon, David P. , Wu, Yougui , Petersen, Ronald C. , Hong, Zhen , DeCarli, Charles , Ding, Ding , Zhao, Qianhua , Galasko, Douglas , Dai, Qi , DeCarli, Charles

Mayo Clinic

American Journal of Alzheimer's Disease & Other Dementias® | February 8, 2010 | Volume: 25 | Issue: 3 | Pages: 233-238

10.1177/1533317509357736 | PMID 20142627 Get It

Objective: To determine apolipoprotein E (APOE)-ε4 and -ε2 frequencies and risk of mild cognitive impairment (MCI) and dementia in Shanghai, China. Methods: A total of 34 MCI and 34 dementia cases were recruited from an urban Memory Disorders Clinic and 32 controls were recruited from a residential community served by the clinic. Apolipoprotein E was genotyped using standard methods. Results: Among controls, frequencies were ε2, 0.11; ε3, 0.84; and ε4, 0.05; among MCI, 0.05, 0.77, and 0.18; and for dementia, 0.02, 0.84, and 0.15, respectively. In education-adjusted models, the odds ratio (OR) = 5.6 for dementia (95% CI = 1.09-29.3) and 4.7 for MCI (95% CI = 0.90-25.2) associated with any ε4 allele. The ε2 allele was inversely associated with dementia (OR = 0.12, 95% CI = 0.013-0.997) and MCI (OR = 0.38, 95% CI = 0.08-1.61). Conclusions: APOE-ε4 increases and -ε2 decreases the risk of dementia vs normal cognition. Similar trends were observed for amnestic mild cognitive impairment (aMCI).
S4‐04‐04: Clinical Practices Regarding Mild Cognitive Impairment (MCI) Among Neurology Service Providers
Roberts, Scott, Uhlmann, Wendy R. , Petersen, Ronald C. , Karlawish, Jason , Green, Robert C.

Mayo Clinic

Alzheimer's & Dementia | January 7, 2010 | Volume: 5 | Issue: 4S_Part_5 | Pages: No page available

10.1016/j.jalz.2009.07.131 Get It

Association of C‐reactive protein with mild cognitive impairment
Roberts, Rosebud O., Geda, Yonas E. , Christianson, Teresa J., Tangalos, Eric G., Ivnik, Robert J., Petersen, Ronald C. , Knopman, David S. , Boeve, Bradley F. , Pankratz, V. Shane , Kullo, Iftikhar J. , Geda, Yonas E

Mayo Clinic

Alzheimer's & Dementia | September 13, 2009 | Volume: 5 | Issue: 5 | Pages: 398-405

10.1016/j.jalz.2009.01.025 | PMID 19751919 Get It

Background Inflammation is proposed to play a role in the development of Alzheimer's disease, and may also be involved in the pathogenesis of mild cognitive impairment (MCI). This study examined the association of inflammatory markers in serum or plasma with prevalent MCI and MCI subtypes in a population‐based sample. Methods Olmsted County, MN, residents aged 70–89 years on October 1, 2004, were evaluated using the Clinical Dementia Rating Scale, a neurological evaluation, and neuropsychological testing. Information ascertained for each participant was reviewed by an expert panel of neuropsychologists, physicians, and nurses, and a diagnosis of normal cognition, MCI, or dementia was made by consensus. C‐reactive protein (CRP), interleukin‐6 (IL‐6), tumor necrosis alpha (TNFα), and adiponectin were measured at baseline. Results Among 313 subjects with MCI and 1570 cognitively normal subjects, a CRP level in the upper quartile (>3.3 mg/L) was significantly associated with MCI (odds ratio [OR], 1.42; 95% confidence interval [CI], 1.00–2.01) and with nonamnestic MCI (OR, 2.05; 95% CI, 1.12–3.78) after adjusting for age, sex, and years of education. However, there was no association with amnestic MCI (OR, 1.21; 95% CI, 0.81–1.82). No association was observed with the other inflammatory markers. Conclusions Plasma CRP is associated with prevalent MCI and with nonamnestic MCI in elderly, nondemented persons in a population‐based setting. These findings suggest the involvement of inflammation in the pathogenesis of MCI.
Creating a transatlantic research enterprise for preventing Alzheimer's disease
Khachaturian, Zaven S., Camı́, Jordi , Andrieu, Sandrine , Ávila, Jesús , Boada, Merçé , Breteler, Monique M.B. , Gauthier, Serge , Gómez‐Isla, Teresa , Khachaturian, Ara S. , Kuller, Lewis H. , Martínez‐Lage, J. M., Petersen, Ronald C., Schellenberg, Gerard D., Sunyer, Jordi , Vellas, Bruno , Bain, Lisa J. , Froelich, Lutz , Larson, Eric B. , López, Oscar L. , Boada, Merce

Mayo Clinic

Alzheimer's & Dementia | June 26, 2009 | Volume: 5 | Issue: 4 | Pages: 361-366

10.1016/j.jalz.2009.05.158 | PMID 19560106 Get It

In recognition of the global problem posed by Alzheimer's disease and other dementias, an international think‐tank meeting was convened by Biocat, the Pasqual Maragall Foundation, and the Lou Ruvo Brain Institute in February 2009. The meeting initiated the planning of a European Union‐North American collaborative research enterprise to expedite the delay and ultimate prevention of dementing disorders. The key aim is to build parallel and complementary research infrastructure that will support international standardization and inter‐operability among researchers in both continents. The meeting identified major challenges, opportunities for research resources and support, integration with ongoing efforts, and identification of key domains to influence the design and administration of the enterprise.